Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) have received a consensus recommendation of “Moderate Buy” from the twelve ratings firms that are currently covering the stock, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating on the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $41.8333.

A number of research firms have weighed in on STOK. BTIG Research reiterated a “buy” rating and set a $39.00 price target on shares of Stoke Therapeutics in a research note on Thursday, March 19th. Needham & Company LLC lifted their price objective on Stoke Therapeutics from $35.00 to $40.00 and gave the company a “buy” rating in a report on Tuesday, March 17th. Loop Capital set a $35.00 price objective on Stoke Therapeutics in a report on Monday, January 5th. Wall Street Zen cut Stoke Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 21st. Finally, Guggenheim began coverage on Stoke Therapeutics in a report on Thursday, February 5th. They set a “buy” rating and a $60.00 price objective for the company.

Insider Activity at Stoke Therapeutics

In other Stoke Therapeutics news, General Counsel Jonathan Allan sold 4,628 shares of Stoke Therapeutics stock in a transaction on Wednesday, March 18th. The stock was sold at an average price of $31.34, for a total transaction of $145,041.52. Following the completion of the transaction, the general counsel directly owned 28,836 shares of the company’s stock, valued at approximately $903,720.24. This trade represents a 13.83% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Thomas Leggett sold 2,382 shares of Stoke Therapeutics stock in a transaction on Wednesday, March 18th. The shares were sold at an average price of $31.34, for a total value of $74,651.88. Following the transaction, the chief financial officer directly owned 10,172 shares of the company’s stock, valued at approximately $318,790.48. The trade was a 18.97% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 69,699 shares of company stock valued at $2,526,714. Insiders own 9.50% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Principal Financial Group Inc. bought a new position in shares of Stoke Therapeutics in the third quarter valued at about $1,062,000. Penserra Capital Management LLC bought a new position in shares of Stoke Therapeutics in the third quarter valued at about $3,539,000. Vanguard Group Inc. raised its holdings in shares of Stoke Therapeutics by 7.4% in the third quarter. Vanguard Group Inc. now owns 3,163,874 shares of the company’s stock valued at $74,351,000 after buying an additional 217,616 shares during the last quarter. Baillie Gifford & Co. bought a new position in shares of Stoke Therapeutics in the fourth quarter valued at about $7,837,000. Finally, Checkpoint Capital L.P. bought a new position in shares of Stoke Therapeutics in the third quarter valued at about $4,983,000.

Stoke Therapeutics Price Performance

STOK opened at $33.08 on Friday. Stoke Therapeutics has a fifty-two week low of $8.30 and a fifty-two week high of $40.22. The firm’s fifty day moving average price is $34.48 and its two-hundred day moving average price is $32.08. The company has a market capitalization of $2.06 billion, a P/E ratio of -275.64 and a beta of 1.20.

Stoke Therapeutics (NASDAQ:STOK) last posted its quarterly earnings results on Monday, March 16th. The company reported ($0.97) earnings per share for the quarter. Stoke Therapeutics had a negative return on equity of 2.05% and a negative net margin of 3.73%.The business had revenue of $1.40 million for the quarter. On average, equities research analysts expect that Stoke Therapeutics will post -3.41 EPS for the current fiscal year.

Stoke Therapeutics Company Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.